Demethoxycurcumin was prior to temozolomide on inhibiting proliferation and induced apoptosis of glioblastoma stem cells

Tumor Biology

Volumn 36, Issue 9, 2015, Pages 7107-7119

  Shi, Lei ^a   Fei, Xifeng ^b   Wang, Zhimin ^b  

^a KUNSHAN FIRST PEOPLE S HOSPITAL AFFILIATED TO JIANGSU UNIVERSITY   (China)

^b Suzhou Kowloon Hospital Affiliated with Shanghai Jiao Tong University School of Medicine   (China)

Author keywords

Apoptosis; Demethoxycurcumin; Glioblastoma stem cell; Proliferation; Temozolomide

Indexed keywords

CASPASE 3; DEMETHOXYCURCUMIN; GLIAL FIBRILLARY ACIDIC PROTEIN; JANUS KINASE; LIPOCORTIN 5; MONOCLONAL ANTIBODY; PROTEIN BCL 2; PROTEIN BCL XL; REACTIVE OXYGEN METABOLITE; STAT3 PROTEIN; TEMOZOLOMIDE; CURCUMIN; DACARBAZINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER GROWTH; CARCINOGENICITY; CELL GROWTH; CELL PROLIFERATION; CELL SIGNALING ASSAY; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; PRIORITY JOURNAL; STEM CELL; ANALOGS AND DERIVATIVES; CANCER STEM CELL; DRUG EFFECTS; GENETICS; METABOLISM; PATHOLOGY; PRIMARY CELL CULTURE; SIGNAL TRANSDUCTION;

APOPTOSIS; CASPASE 3; CELL PROLIFERATION; CURCUMIN; DACARBAZINE; GLIOBLASTOMA; HUMANS; NEOPLASTIC STEM CELLS; PRIMARY CELL CULTURE; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION;

EID: 84947129144     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3427-x     Document Type: Article

References (39)

1. Stupp R, Tonn JC, Brada M, Pentheroudakis G, ESMO Guidelines Working Group. High-grade malignant glioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21 Suppl 5:v190–3.
2. Clarke MJ, Mulligan EA, Grogan PT, Mladek AC, Carlson BL, Schroeder MA, et al. Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines. Mol Cancer Ther. 2009;8(2):407–14.
3. Athanassiou H, Synodinou M, Maragoudakis E, Paraskevaidis M, Verigos C, Misailidou D, et al. Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. J Clin Oncol. 2005;23(10):2372–7.
4. Vescovi AL, Galli R, Reynolds BA. Brain tumour stem cells. Nat Rev Cancer. 2006;6(6):425–36.
5. Braine J, Herpin F. Molecular hydrogen beyond the optical edge of an isolated spiral galaxy. Nature. 2004;432(7015):369–71.
6. Chen J, Fu X, Wan Y, Wang Z, Jiang D, Shi L. miR-125b inhibitor enhance the chemosensitivity of glioblastoma stem cells to temozolomide by targeting Bak1. Tumour Biol. 2014;35(7):6293–302.
7. Ruby AJ, Kuttan G, Babu KD, Rajasekharan KN, Kuttan R. Anti-tumourand antioxidant activity of natural curcuminoids. Cancer Lett. 1995;94(1):79–83.
8. Luthra PM, Kumar R, Prakash A. Demethoxycurcumin induces Bcl-2 mediated G2/M arrest and apoptosis in human glioma U87 cells. Biochem Biophys Res Commun. 2009;384(4):420–5.
9. Darling JL. The in vitro biology of human brain tumors. In: Thomas DGT, editor. Neuro-oncology: primary malignant brain tumors. Baltimore: Johns Hopkins University Press; 1990. p. 1–25.
10. Shi L, Zhang J, Pan T, Zhou J, Gong W, Liu N, et al. MiR-125b is critical for the suppression of human U251 glioma stem cell proliferation. Brain Res. 2010;1312:120–6.
11. Shi L, Chen J, Wang YY, Sun G, Liu JN, Zhang JX, et al. Gossypin induces G2/M arrest in human malignant glioma U251 cells by the activation of Chk1/Cdc25C pathway. Cell Mol Neurobiol. 2012;32(2):289–96.
12. Zhang S, Wan Y, Pan T, Gu X, Qian C, Sun G, et al. MicroRNA-21 inhibitor sensitizes human glioblastoma U251 stem cells to chemotherapeutic drug temozolomide. J Mol Neurosci. 2012;47(2):346–56.
13. Huang TY, Hsu CW, Chang WC, Wang MY, Wu JF, Hsu YC. Demethoxycurcumin retards cell growth and induces apoptosis in human brain malignant glioma GBM 8401 cells. Evid Based Complement Alternat Med. 2012;2012:396573.
14. Gong X, Schwartz PH, Linskey ME, Bota DA. Neural stem/progenitors and glioma stem-like cells have differential sensitivity to chemotherapy. Neurology. 2011;76(13):1126–34.
15. Narayan P, Mentzer Jr RM, Lasley RD. Annexin V staining during reperfusion detects cardiomyocytes with unique properties. Am J Physiol Heart Circ Physiol. 2001;281(5):H1931–7.
16. Sandur SK, Pandey MK, Sung B, Ahn KS, Murakami A, Sethi G, et al. Curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin and turmerones differentially regulate anti-inflammatory and anti-proliferative responses through a ROS-independent mechanism. Carcinogenesis. 2007;28(8):1765–73.
17. Lee JW, Hong HM, Kwon DD, Pae HO, Jeong HJ. Dimethoxycurcumin, a structural analogue of curcumin, induces apoptosis in human renal carcinoma caki cells through the production of reactive oxygen species, the release of cytochrome C, and the activation of caspase-3. Korean J Urol. 2010;51(12):870–8.
18. Oliva CR, Moellering DR, Gillespie GY, Griguer CE. Acquisition of chemoresistance in gliomas is associated with increased mitochondrial coupling and decreased ROS production. PLoS ONE. 2011;6(9):e24665.
19. Yu M, Zheng Y, Sun HX, Yu DJ. Inhibitory effects of enalaprilat on rat cardiac fibroblast proliferation via ROS/P38MAPK/TGF-β1 signaling pathway. Molecules. 2012;17(3):2738–51.
20. Ravindran J, Prasad S, Aggarwal BB. Curcumin and cancer cells: how many ways can curry kill tumor cells selectively? AAPS J. 2009;11(3):495–510.
21. Barré B, Avril S, Coqueret O. Opposite regulation of Myc and p21waf1 transcription by STAT3 proteins. J Biol Chem. 2003;278(5):2990–6.
22. Zhong K, Song W, Wang Q, Wang C, Liu X, Chen D, et al. Murine myeloid dendritic cells that phagocytose apoptotic T cells inhibit the immune response via NO. PLoS ONE. 2012;7(11):e49378.
23. Ji JD, Kim HJ, Rho YH, Choi SJ, Lee YH, Cheon HJ, et al. Inhibition of IL-10-induced STAT3 activation by 15-deoxy-delta12,14-prostaglandin J2. Rheumatology (Oxford). 2005;44(8):983–8.
24. Bojes HK, Suresh PK, Mills EM, Spitz DR, Sim JE, Kehrer JP. Bcl-2 and Bcl-xL in peroxide-resistant A549 and U87MG cells. Toxicol Sci. 1998;42(2):109–16.
25. Terrano DT, Upreti M, Chambers TC. Cyclin-dependent kinase 1-mediated Bcl-xL/Bcl-2 phosphorylation acts as a functional link coupling mitotic arrest and apoptosis. Mol Cell Biol. 2010;30(3):640–56.
26. Shieh JM, Chen YC, Lin YC, Lin JN, Chen WC, Chen YY, et al. Demethoxycurcumin inhibits energy metabolic and oncogenic signaling pathways through AMPK activation in triple-negative breast cancer cells. J Agric Food Chem. 2013;61(26):6366–75.
27. Ni X, Zhang A, Zhao Z, Shen Y, Wang S. Demethoxycurcumin inhibits cell proliferation, migration and invasion in prostate cancer cells. Oncol Rep. 2012;28(1):85–90.
28. Hsu YC, Weng HC, Lin S, Chien YW. Curcuminoids-cellular uptake by human primary colon cancer cells as quantitated by a sensitive HPLC assay and its relation with the inhibition of proliferation and apoptosis. J Agric Food Chem. 2007;55(20):8213–22.
29. Selvendiran K, Koga H, Ueno T, Yoshida T, Maeyama M, Torimura T, et al. Luteolin promotes degradation in signal transducer and activator of transcription 3 in human hepatoma cells: an implication for the antitumor potential of flavonoids. Cancer Res. 2006;66(9):4826–34.
30. Dayem AA, Choi HY, Kim JH, Cho SG. Role of oxidative stress in stem, cancer, and cancer stem cells. Cancers (Basel). 2010;2(2):859–84.
31. Jiang JY, Sun Y, Yuan Y. Mechanism of temozolomide-induced anti-tumor effects on glioblastoma cells in vitro is via ROS-dependent SIRT1 signaling pathway. Zhonghua Zhong Liu Za Zhi. 2012;34(10):734–8.
32. Garrido C, Galluzzi L, Brunet M, Puig PE, Didelot C, Kroemer G. Mechanisms of cytochrome c release from mitochondria. Cell Death Differ. 2006;13(9):1423–33.
33. Senft C, Polacin M, Priester M, Seifert V, Kögel D, Weissenberger J. The nontoxic natural compound curcumin exerts anti-proliferative, anti-migratory, and anti-invasive properties against malignant gliomas. BMC Cancer. 2010;10:491.
34. Shi L, Wan Y, Sun G, Zhang S, Wang Z, Zeng Y. miR-125b inhibitor may enhance the invasion-prevention activity of temozolomide in glioblastoma stem cells by targeting PIAS3. BioDrugs. 2014;28(1):41–54.
35. Dauer DJ, Ferraro B, Song L, Yu B, Mora L, Buettner R, et al. Stat3 regulates genes common to both wound healing and cancer. Oncogene. 2005;24(21):3397–408.
36. Rahaman SO, Harbor PC, Chernova O, Barnett GH, Vogelbaum MA, Haque SJ. Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells. Oncogene. 2002;21(55):8404–13.
37. Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res. 2002;8(4):945–54.
38. Wang J, Wang H, Li Z, Wu Q, Lathia JD, McLendon RE, et al. c-Myc is required for maintenance of glioma cancer stem cells. PLoS ONE. 2008;3(11):e3769.
39. Zhou Z, Sun L, Wang Y, Wu Z, Geng J, Miu W, et al. Bone morphogenetic protein 4 inhibits cell proliferation and induces apoptosis in glioma stem cells. Cancer Biother Radiopharm. 2011;26(1):77–83.